Trial Profile
A Phase III Multi-national, Multi-centre, Open Label, Safety Study to Assess the Safety of Re-exposure After a Variable Interval and Subsequent Chronic Therapy With the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed at Weeks 0, 2 and 4 Then Every 4 Weeks), in the Treatment of Patients With Active Crohn's Disease Who Have Previously Been Withdrawn From Studies CDP870-031 or CDP870-032 Due to an Exacerbation of Crohn's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Acronyms PRECiSE 4
- Sponsors UCB; UCB Pharma SA
- 16 May 2015 Seven-year results from PRECiSE 4 presented at Digestive Disease Week 2015, according to a UCB media release.
- 27 Jun 2013 New trial record